<DOC>
	<DOCNO>NCT01730586</DOCNO>
	<brief_summary>The goal clinical research study learn abraxane help control colorectal and/or small bowel cancer . The safety drug also study . Abraxane design block cancer cell divide , may cause die .</brief_summary>
	<brief_title>Abraxane CIMP-High Colorectal Small Bowel Adenocarcinomas</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive study drug 21-day study cycle . You receive abraxane vein 30 minute Day 1 cycle . Study Visits : On Day 1 cycle , follow test procedure perform : - You physical exam , include measurement weight blood pressure . - You ask drug may take symptom side effect may . - Your performance status record . - Blood ( 2 tablespoon ) draw routine test . At end every 3rd cycle ( Cycles 3 , 6 , 9 ) : Â°You CT MRI scan chest , abdomen , pelvis check status disease . If point scan show disease appear get good , another scan 2 cycle later . Length Treatment : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect , study stop , unable follow study instruction . Your participation study follow-up period . End-of-Treatment Visit : Within 10 day stop take study drug , end-of-treatment visit . At visit , follow test procedure perform : - You physical exam , include measurement weight blood pressure . - You ask drug may take symptom side effect may . - Your performance status record . - Blood ( 2 tablespoon ) draw routine test . - If one perform previous 4 week , CT MRI scan chest , abdomen , pelvis check status disease . Follow-Up : The study staff ask symptom side effect may 30 day last dose study drug . The study staff may ask phone time routine clinic visit . If study staff contact phone , phone call last 15-30 minute . If leave study reason disease get bad , CT MRI scan chest , abdomen , pelvis check status disease every 12 week unless start receive treatment . The study staff also review medical record and/or contact check status disease every 3 month stop receive study drug . If contact phone , phone call take 5 minute . This investigational study . Abraxane FDA approve commercially available treatment breast cancer . It FDA approve treatment colorectal small bowel cancer . The use abraxane patient colorectal cancer small bowel cancer investigational . Up 35 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient must histologically cytologically confirm colorectal adenocarcinoma small bowel adenocarcinoma 2 . Metastatic disease document diagnostic imaging study measurable disease per RECIST version 1.1 . 3 . Refractory disease define : ) prior treatment fluoropyrimidine , oxaliplatin , irinotecan , antiepidermal growth factor receptor ( EGFR ) therapy Kirsten rat sarcoma ( KRAS ) wildtype colorectal adenocarcinoma ; b ) prior treatment fluoropyrimidine oxaliplatin small bowel adenocarcinoma . 4 . Colorectal adenocarcinoma patient must know CpG island methylator phenotype . CIMPhigh phenotype define hypermethylation 2 6 methylationspecific PCR marker ( hMLH1 , P16 , P14 , MINT1 , MINT2 , MINT31 ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . 6 . Adequate organ function include : ) Absolute neutrophil count ( ANC ) =/ &gt; 1,500cells/mm^3 ; b ) Platelets =/ &gt; 100,000/ul ; c ) Hemoglobin &gt; 9.0 g/dL ; ) Total bilirubin =/ &lt; 1.5mg/dL In patient know Gilbert 's syndrome , direct bilirubin =/ &lt; 1.5 x upper limit normal ( ULN ) use organ function criterion , instead total bilirubin ; e ) AST ALT &lt; 2.5 x ULN ; f ) Alkaline phosphatase &lt; 2.5x ULN ; g ) Creatinine &lt; 1.5 gm/dL . 7 . Negative serum urine pregnancy test woman childbearing potential ( WOCBP ) define postmenopausal 12 month previous surgical sterilization , within one week prior initiation treatment . WOCBP must use adequate method contraception avoid pregnancy throughout study 12 week last dose study drug minimize risk pregnancy . 8 . A male subject father potential must use adequate method contraception avoid conception throughout study 12 week last dose study drug minimize risk pregnancy . If partner pregnant breastfeeding , subject must use condom . 9 . Patients must sign Informed Consent Authorization indicate aware investigational nature study know risk involve . 10 . Patient =/ &gt; 18 year age day consent study . 1 . Peripheral neuropathy grade 2 great Common Terminology Criteria Adverse Events ( CTCAE ) 4.0 . In CTCAE version 4.0 grade 2 sensory neuropathy define `` moderate symptom ; limit instrumental activity daily live ( ADLs ) '' . 2 . Prior treatment taxane therapy either colorectal cancer small bowel adenocarcinoma . 3 . Chemotherapy investigational agent within 14 day first receipt study treatment , major surgery within 28 day first receipt study treatment , palliative radiation within 7 day first receipt study treatment . 4 . Concurrent severe and/or uncontrolled medical condition could compromise participation study unstable angina , myocardial infarction within 6 month , unstable symptomatic arrhythmia , uncontrolled diabetes , serious active uncontrolled infection . 5 . Pregnancy ( positive pregnancy test ) lactation . 6 . Patients carcinomatous meningitis . 7 . Known central nervous system ( CNS ) disease , except treat brain metastasis . Treated brain metastasis define evidence progression hemorrhage treatment ongoing requirement dexamethasone , ascertain clinical examination brain imaging ( MRI CT ) screen period . Anticonvulsants ( stable dose ) allow . Treatment brain metastasis may include whole brain radiotherapy ( WBRT ) , radiosurgery ( RS ; Gamma Knife , LINAC , equivalent ) combination deem appropriate treating physician . Patients CNS metastasis treat neurosurgical resection brain biopsy perform within 3 month prior Day 1 exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Cancer Gastrointestinal Tract</keyword>
	<keyword>CIMP-high Colorectal Adenocarcinoma</keyword>
	<keyword>Small Bowel Adenocarcinomas</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Small bowel cancer</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Paclitaxel ( Protein-Bound )</keyword>
	<keyword>ABI-007</keyword>
</DOC>